Healthcare Sales & Marketing Network News: ADPKD

Searching News Database: ADPKD

HSMN NewsFeed - 18 Sep 2025
J & D Pharmaceuticals LLC Receives Orphan Drug Designation for Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Apr 2025
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 23 Jun 2023
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Nov 2022
Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Jun 2017
Regulus Announces Pipeline Updates and Advancements
Biopharmaceuticals

HSMN NewsFeed - 24 Mar 2014
Otsuka Pharmaceutical's Samsca(R) Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Dec 2013
European Medicines Agency (EMA) Accepts Otsuka's Marketing Authorisation Application (MAA) for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Biopharmaceuticals Regulatory

Return to NewsFeed

Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 2 additional stories matching:
ADPKD
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.